8103. Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021.
This study updates an analysis of US mortality in 2020, including deaths due to COVID-19 as well as all other causes.
8112. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.
作者: Domenico Luca Grieco.;Luca S Menga.;Melania Cesarano.;Tommaso Rosà.;Savino Spadaro.;Maria Maddalena Bitondo.;Jonathan Montomoli.;Giulia Falò.;Tommaso Tonetti.;Salvatore L Cutuli.;Gabriele Pintaudi.;Eloisa S Tanzarella.;Edoardo Piervincenzi.;Filippo Bongiovanni.;Antonio M Dell'Anna.;Luca Delle Cese.;Cecilia Berardi.;Simone Carelli.;Maria Grazia Bocci.;Luca Montini.;Giuseppe Bello.;Daniele Natalini.;Gennaro De Pascale.;Matteo Velardo.;Carlo Alberto Volta.;V Marco Ranieri.;Giorgio Conti.;Salvatore Maurizio Maggiore.;Massimo Antonelli.; .
来源: JAMA. 2021年325卷17期1731-1743页
High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19.
8116. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
作者: Domenica Rubino.;Niclas Abrahamsson.;Melanie Davies.;Dan Hesse.;Frank L Greenway.;Camilla Jensen.;Ildiko Lingvay.;Ofri Mosenzon.;Julio Rosenstock.;Miguel A Rubio.;Gottfried Rudofsky.;Sayeh Tadayon.;Thomas A Wadden.;Dror Dicker.; .
来源: JAMA. 2021年325卷14期1414-1425页
The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.
|